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Abstract Two young girls without a notable medical
history except for asthma presented with an acute toxic
encephalopathy with very low serine concentrations both in
plasma and cerebrospinal fluid (CSF) comparable to
patients with 3-phosphoglycerate dehydrogenase (3-PGDH)
deficiency. Clinical symptoms and enzyme measurement
(in one patient) excluded 3-PGDH deficiency. Deficiencies
in other serine biosynthesis enzymes were highly unlikely
on clinical grounds. On basis of the fasting state, ketone
bodies and lactate in plasma, urine and CSF, we speculate
that reduced serine levels were due to its use as gluconeo-
genic substrate, conversion to pyruvate by brain serine
racemase or decreased L-serine production because of a
lack of glucose. These are the first strikingly similar cases
of patients with a clear secondary serine deficiency
associated with a toxic encephalopathy.
Introduction
L-Serine, a nonessential amino acid, plays an important role
in cellular proliferation (Snell 1984). In addition, L-serine is
the precursor of the neurotransmitters D-serine and glycine
and is involved in one-carbon metabolism. L-Serine can be
derived from different sources, such as dietary intake,
degradation of proteins and phospholipids, and glucose via
the glycolytic intermediates 3-phosphoglycerate and 3-
phosphohydroxypyruvate (de Koning et al. 2003).
Three enzymes are involved in serine biosynthesis:
3-phosphoglycerate dehydrogenase (3-PGDH), 3-
phosphohydroxypyruvate aminotransferase, and phospho-
serine phosphatase. Genetic 3-PGDH deficiency (Jaeken et
al. 1996; de Koning et al. 2000) is associated with
congenital microcephaly, severe psychomotor retardation,
and intractable seizures (de Koning et al. 2004). The
biochemical hallmark of this disorder is a significantly
reduced concentration of L-serine and, to a variable degree,
glycine, in cerebrospinal fluid (CSF) and plasma (de
Koning et al. 2000). Deficiencies of the other two enzymes
involved in the L-serine biosynthesis show clinical pheno-
types (severe neurological symptoms, severe psychomotor
retardation, and seizures) similar to that found in 3-PGDH
deficiency (Hart et al. 2007; Jaeken et al. 1997; Veiga-da-
Cunha et al. 2004). Decreased serine in CSF has also been
described in cases in which the biochemical defect
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remained unsolved. One of these patients showed growth
retardation, progressive polyneuropathy, and ichthyosis;
supplementation with L-serine produced clinical improve-
ment (Catsman-Berrevoets et al. 1997).
Here we describe two patients with severe encephalopa-
thy associated with a viral infection and serine deficiency in
plasma and CSF. In the medical histories, asthma is the only
notable clinical condition. Possible mechanisms for the
extremely low serine concentrations in CSF are discussed.
Patient 1
A 7-year old, normally developing girl was diagnosed with
moderately severe asthma for which she used inhalation
therapy with combination of salmeterol/fluticasone. The
day before her death, she presented with a mild febrile
condition, including malaise, headache, and nausea. Med-
ical examination showed no abnormality, and domperidone
was prescribed. The morning before her death, her mother
found her unresponsive in bed, probably following a
seizure. At that time, blood glucose, as measured by a
bed-side apparatus, was 2.1 mmol/l. In the emergency
room, the patient had convulsions, which responded to
diazepam. Physical examination showed expiratory wheez-
ing, normal blood pressure and capillary refill time, a
relatively low heart rate (100/min), no hepatosplenomegaly,
normal pupils, and no signs of trauma or bleeding.
Hypoglycemia or electrolyte disturbances were excluded.
Liver enzymes and bilirubin were slightly elevated, and
blood ammonia was normal (15 µmol/l). She regained
consciousness for 1.5 h but became progressively dyspneic
and presented suddenly with apnea and desaturation,
decortication rigidity, bilateral fixed mydriatic pupils, and
deep coma. She was intubated and treated with dexameth-
asone and mannitol. A brain computed tomography (CT)
scan showed bilateral central herniation and cerebral
edema. There were indisputable signs of brain death, and
she died 24 h after the first symptoms.
Amino acid analysis of both plasma and CSF revealed
strongly decreased serine concentrations (Tables 1, 2, 3)
Table 1 Summary of cerebral spinal fluid (CSF) and plasma amino acids in the two patients dying from brain-stem compression after acute
cerebral edema
Amino acid Measurement Reference values
CSF (µmol/l) Plasma Ratio CSF (µmol/l) Plasma Ratio
Serine Patient 1 8 31 0.258 19–38 95–166 0.276±0.053
Patient 2 7 33 0.242
Serine (3-PGDH def)a 6–8 28–64
Glycine Patient 1 5 107 0.047 0.7–15 139–317 <0.0400
Patient 2 6 185 0.032
Glycine (3-PGDH def)a 1–4 128–190
Threonine Patient 1 17 61 0.279 22–47 49–183 0.291±0.053
Patient 2 11 29 0.379
Alanine Patient 1 14 72 0.194 8–42 153–560 0.112±0.028
Patient 2 37 181 0.204
CSF cerebral spinal fluid, 3-PGDH 3-phosphohydroxypyruvate aminotransferase
a de Koning et al. 2004
Table 2 Plasma concentrations of all amino acids (µmol/l) in the two
patients
Amino acid Patient 1 Patient 2 Reference values
Taurine 21 72 9–130
Threonine 61 29 49–183
Serine 31 33 95–166
Asparagine 18 6 18–69
Glutamic acid 23 28 1–105
Glutamine 301 262 317–757
Proline 70 149 26–412
Glycine 107 185 139–317
Alanine 72 181 153–560
Citrulline 15 4 10–57
Valine 158 73 120–323
Cystine 6 18 0–42
Methionine 9 7 13–38
Isoleucine 59 13 24–100
Leucine 120 48 49–179
Tyrosine 36 43 30–109
Phenylalanine 70 46 28–92
Ornithine 34 12 30–96
Lysine 96 47 81–217
Histidine 89 47 55–104
Arginine 38 31 29–124
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comparable with levels observed in patients with 3-PGDH
deficiency (de Koning et al. 2004). Enantiomer separation
revealed D-serine to be 0.9 µmol/L (ref. 0.8–4.3 µmol/L)
and L-serine 4.0 µmol/L (ref. 17.2–44.0 µmol/L), with
slightly elevated D-serine/total serine ratio of 18% in CSF
(Fuchs et al. 2006). Concentrations of the other amino acids
were normal or decreased according to a nonspecific pattern
(data not shown). A deficiency of 3-phosphoglycerate
dehydrogenase was excluded in cultured fibroblasts
(43 nmol/mg per min; normal 29.5±2.7 nmol/mg per
min). Further metabolic screening revealed increased
ketone bodies and lactate in urine, plasma, and CSF
(Table 4). Plasma acylcarnitine profile showed an elevated
concentration of OH-C4-carnitine. A fatty acid oxidation
defect was excluded. Brain microscopy showed bilateral
necrosis in the cerebral tonsils compatible with central
herniation. No signs of encephalitis or meningitis were
found, but diffuse interstitial edema was obviously present.
Postmortem microbiology sampling yielded a parainfluenza
type II virus in the lungs, probably explaining fever onset
and asthmatic signs as her presenting condition. The
clinical picture probably reflects a toxic encephalopathy.
Patient 2
A 4-year-old girl with normal mental development
suffered from asthma for which she used Flixotide (a
steroid, 2 dd 250 µg) and salmeterol (2 dd 25 µg). She
had normal height but severe malnutrition [weight<2
standard deviations (SD)] due to feeding difficulties
related to behavioral problems. Because of sleep dis-
turbances, the patient had been on treatment with
Alimemazine (an antihistaminic sedative agent) for 4
months. Two days before her death (in the evening, day
1), she presented with fever (39–40°C) without other
particularities. The next morning (day 2), she was
found in bed with tonic clonic seizures. The seizures
were resistant to multiple anticonvulsive drugs. There
were no signs of respiratory or circulatory failure. On
admission, serum glucose was 4.0 mmol/L, with CSF
glucose 1.0 mmol/L; serum electrolytes were normal, as
was blood ammonia (15 µmol/l). There were no signs
of a bacterial central nervous system (CNS) infection in
CSF, no pleocytosis, and bacterial and viral cultures
remained negative; later nasal cultures, however,
showed an adenovirus V. Blood C-reactive protein
(CRP) was>300 mg/ml.
Physical examination showed a very ill girl with coma
scores E1, M4, V1. Intubation and cardiac support were
effective for some hours, but a rapid deterioration was seen
with an isoelectric electroencephalogram (EEG) pattern and
absent stem reflexes. After a repeated isoelectric EEG, the
next day, supportive treatment was discontinued. No
postmortem examination was performed. Metabolic
investigations in plasma and CSF taken at day 2 showed
particularly low plasma and CSF serine concentrations.
Concentrations of the other amino acids were normal or
decreased according to a nonspecific pattern (data not
Table 3 CSF concentrations of all amino acids (µmol/l) in the two
patients
Amino acid Patient 1 Patient 2 Reference values
Taurine 10 4 2–12
Threonine 1 11 22–47
Serine 8 7 19–38
Asparagine 4 6 2–17
Glutamic acid 1 0–16
Glutamine 380 357 234–689
Proline 1 0 0–2
Glycine 5 6 1–15
Alanine 14 37 8–42
Citrulline 3 1 0–3
Valine 15 17 8–24
Cystine 1 4 0–2
Methionine 3 5 0–7
Isoleucine 5 0 2–11
Leucine 18 9 6–21
Tyrosine 2 6 0–25
Phenylalanine 28 24 6–19
Ornithine 43 4 1–9
Lysine 31 13 8–35
Histidine 32 21 4–23
Arginine 20 5 4–35











Patient 1 374 (<56) 22410 (<5) 2308 (<1700) 1731 (<280) n.d.
Patient 2a 130 (< 56) 317 (< 5) 7200 (<1700) n.d. 2200 (<5)
nd, not determined
Urine and plasma from patient 1 were collected the day before death.
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shown). Unfortunately, no fibroblasts were available for
analysis of 3-PGDH activity. Plasma lactate and 3-
hydroxybutyrate were clearly increased, as was CSF
lactate (Table 4). Urine organic acid analysis showed a
moderate ketonuria as well as a marginally elevated lactate
excretion.
Discussion
Here we present two young female patients with extremely
low serine concentrations in CSF and plasma comparable
with 3-PGDH-deficient patients without clinical features
suggestive for a serine biosynthesis defect. Both patients
showed a rapidly progressive toxic encephalopathy and
brain edema causing death within 24 h after the first
symptoms. Acute toxic encephalopathy has been de-
scribed in young children (2–3 years of age) without a
notable medical history (de Jong-de Vos van Steenwijk et
al. 1981), with cerebral edema and fatal brain-stem
compression as the major cause of death. Possible triggers
include infections by several bacteria or viruses. Our
patients suffered from parainfluenza virus type II (patient
1) and a nasal adenovirus 5 (patient 2), respectively. Both
viruses have been associated with acute encephalopathy
(Hata et al. 2007; Straussberg et al. 2001). The pathogen-
esis of acute toxic encephalopathy has not been elucidated.
Toxins leading to either endothelial cell damage with
disruption of the blood–brain barrier (Ashkenazi et al.
1990) or directly affecting cells leading to cytotoxic
edema (Kimelberg 1995) might play a role. A relationship
between acute encephalopathy and low CSF serine
concentration has never been reported.
Both our patients had an overnight (fasting) period before
serious neurological symptoms occurred. Low plasma con-
centrations of (essential) amino acids and increased ketone
bodies in urine and plasma reflected this fasting state. In
addition, plasma alanine concentrations of 72 µM and
181 µM made a gluconeogenesis defect unlikely. In cases
of fasting in combination with fever/illness, a cerebral
hypoglycemic state could trigger formation of ketone bodies
as an alternative source of energy for the brain. In patient 1,
we confirmed an increased concentration of 3-OH-butyrate
in CSF. In patient 2, the low CSF glucose concentration
relative to plasma concentration might suggest a glucose
transporter 1 (GLUT-1) defect (MIM# 606777) despite the
absence of clinical symptoms of this genetic defect (Wang et
al. 2005); CSF glucose concentration, however, normalized
upon glucose bolus.
In addition to ketone bodies, L-serine is a potential energy
source under certain conditions in cerebral tissue. L-serine
does not easily cross the blood–brain barrier, and glial cells
contain enzymes of the complete serine synthesis and
degradation pathways (Furuya and Watanabe 2003; Mitoma
et al. 1998). Serine racemase, present in different regions of
the brain (de Miranda et al. 2000), can synthesize D-serine,
as well as pyruvate, from L-serine (de Miranda et al. 2002;
Wolosker et al. 2002). The formed pyruvate may act as a
local, emergency energy substrate (Wu et al. 2004). In both
patients with a clear cerebral emergency situation, L-serine
might have been used as an alternative energy source. The
relatively high percentage of D-serine (18% of total serine,
ref. 3–16%) (Fuchs et al. 2006) supports this possibility.
In order to study the role of L-serine in energy
metabolism in the hypoglycemic brain, we analyzed CSF
of four patients diagnosed with a GLUT-1 deficiency. No
changes in amino acids in CSF from these patients were
observed (results not published). From this observation, we
conclude that a chronic low CSF glucose concentration, as
present in GLUT-1-deficient patients, does not explain the
low CSF serine concentration. An alternative explanation
for the low CSF serine concentration is a decreased
production of serine from glucose due to an acute
hypoglycemic state. The low concentration of plasma L-
serine, as observed in our patients, is in line with this idea.
In general, fasting patients show mildly decreased plasma
and CSF serine concentrations (M. Duran, Amsterdam,
personal communication), which are, however, not as low
as those observed in our patients. These observations
indicate that it is probably the extreme local energy deficit
that might contribute to a low cerebral serine concentration.
In addition to hypoglycemia, an increased nicotinamide
adenine dinucleotide, reduced nicotinamide adenine dinu-
cleotide (NADH/NAD+) ratio as seen in anoxia might be
considered as a cause of inhibition of serine synthesis.
However, we observed increased concentrations of CSF L-
serine (threefold) and glycine (tenfold) in patients with
asphyxia compared with controls (data not published).
In summary, we observed low serine concentrations in two
young girls who died from cerebral edema with brainstem
compression. The low serine concentrations were not caused
by an inherited disorder of metabolism but probably reflected
a pathophysiological state of the brain in which L-serine was
either used to produce pyruvate via serine racemase, or L-
serine production failed due to a lack of glucose.
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